Loading…

183MO Capivasertib and fulvestrant (F) for patients (pts) with aromatase inhibitor (AI)-resistant HR+/HER2- advanced breast cancer (ABC): Second progression-free survival (PFS2) and time to first subsequent chemotherapy (TFSC) in the CAPItello-291 trial

Saved in:

Bibliographic Details
Published in:	ESMO open 2024-05, Vol.9, p.103205, Article 103205
Main Authors:	Rugo, H.S., Oliveira, M., Howell, S.J., Dalenc, F., Cortés, J., Moreno, H.L. Gomez, Hu, X., Jhaveri, K., Loibl, S., Murillo, S. Morales, Okera, M., Park, Y.H., Toi, M., Zhukova, L., Fulford, M., D'Cruz, C., Wadsworth, I., Turner, N.
Format:	Article
Language:	English
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!